ArticleIntensive care medicine experimental2026
Quantifying diffuse airspace disease on portable chest radiographs in acute respiratory failure using the RALE score.
Article in Intensive care medicine experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundPortable chest radiographs (CXRs) obtained at presentation of acute respiratory failure (ARF) are interpreted qualitatively to assess airspace disease (ASD) and identify features consistent with acute respiratory distress syndrome (ARDS). The Radiographic Assessment of Lung Edema (RALE) score offers a semiquantitative measure of radiographic ASD, and has demonstrated prognostic value in ARDS, but its ability to quantify radiographic ASD burden across the full spectrum of ARF presentations remains uncertain.
methodsWe analyzed 4,259 portable CXRs from 814 critically ill adults with expert‑adjudicated ARF subtypes, including ARDS, at‑risk for ARDS, cardiogenic pulmonary edema, acute exacerbation of interstitial lung disease (AE‑ILD), acute‑on‑chronic hypercapnic respiratory failure, and airway‑protection intubations. Trained clinicians, blinded to clinical data, assigned RALE scores. Analyses addressed (1) whether RALE distinguishes CXRs without ASD (airway‑protection intubations and acute-on-chronic hypercapnic respiratory failure) from those with any ASD, and (2) among CXRs with ASD, whether RALE quantifies diffuse bilateral opacification, distinguishing extensive from limited parenchymal involvement. Discrimination was evaluated using receiver operating characteristic curves, with sensitivity analyses assessing the influence of image‑quality features.
resultsRALE scores increased stepwise from ASD absent to ASD limited to ASD diffuse, discriminated CXRs with any ASD from those without (area under the curve [AUC] 0.81, 95% confidence interval [CI] 0.77-0.85; rule‑out threshold RALE ≥ 7 yielded 96% sensitivity) and quantified diffuse bilateral opacification among ASD-positive CXRs with moderate accuracy (AUC 0.79, 95% CI 0.75-0.82). RALE distributions overlapped substantially across ARDS, cardiogenic pulmonary edema, and AE‑ILD, reflecting shared radiographic appearances rather than etiologic specificity. Suboptimal penetration inflated RALE scores and markedly reduced discrimination (AUC 0.59 vs 0.83 with adequate penetration).
conclusionsRALE quantifies radiographic ASD burden across the full spectrum of ARF at intubation - discriminating ASD-absent from ASD-present CXRs and stratifying the extent of parenchymal involvement among those with ASD. However, it did not distinguish between clinical syndromes that share similar diffuse radiographic presentations, highlighting the need to interpret RALE within the broader clinical context and ensure adequate image quality for accurate scoring. These findings reflect RALE's nature as a radiographic burden metric rather than a diagnostic classifier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.